Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CCHR Warns Parents About Stimulant Adderall Risks: Illicit Use is “Similar to Taking Meth,” According to Neurologist
  • USA - English


News provided by

Citizens Commission on Human Rights

Feb 29, 2016, 09:00 ET

Share this article

Share toX

Share this article

Share toX


Many people are prescribed Adderall and then sell it for profit, according to neurologist Dr. Don Gervais. He says the effects on the brain are similar to taking meth.

Post this

Los Angeles, California (PRWEB) February 29, 2016 -- Citizens Commission on Human Rights (CCHR), established in 1969 by the Church of Scientology and eminent psychiatrist, Prof. Thomas Szasz, warns parents to be alert to their teen-aged children being illicitly sold the stimulant Adderall (amphetamine and dextroamphetamine) in light of Louisiana neurologist, Don Gervais recent statement that abuse can “lead to progressive and early drug induced Parkinsonism.” Many people are prescribed the drug and then sell it for profit, according to Dr. Gervais. He says the effects on the brain are similar to taking meth.[1]

CCHR points out that the U.S. Drug Enforcement Administration also categorizes Adderall in the same class as highly addictive substances, such as cocaine, morphine and opium.[2] According to a FOX News report, the use and abuse of Adderall is prevalent on high school and college campuses, but the short- and long-term risks of using the prescription drug are still unknown to many.[3]

Meanwhile, a study released in February 2015 from the Johns Hopkins Bloomberg School of Public Health shows that incidences of misuse and emergency room visits related to Adderall also increased dramatically for young adults between 2006 and 2011.[4]

CCHR was contacted by one Los Angeles grandfather, Mr. Luis, whose two school-aged grandchildren were put at risk of being prescribed Adderall when their mother was told both had “ADHD.” Googling for information about ADHD, he and his daughter found CCHR’s website and its Parents Know Your Rights page and CCHR’s Psychiatric Drug Side Effects Searchable Database. “We discovered we were not the only ones with this concern,” Mr. Luis stated.

The Luis family is one example of the scores of parents contacting CCHR to obtain facts about what has become a $9.9 billion a year in drug sales ADHD industry because they are not obtaining the information through prescribers. According to the IMS Vector One database, in 2013, 62,843 0-5 year olds were taking Adderall (or a generic version of it).[5]

Whether it is the school complaining about a child’s behavior, or the parent observing emotional or educational problems, CCHR says parents are being told their child has a “mental disorder” that needs “medication”—often powerful stimulants like Adderall. However, experts say ADHD is not a “neurobiological condition,” as parents are frequently told:

• A study by Lydia Furman, published in the Journal of Child Neurology, admitted: “In summary, the working dogma that ADHD is a disease or neurobehavioral condition does not at this time hold up to scrutiny of evidence.”[6]
• Court expert, Dr. Toby Watson, PsyD., says, “Psychological and psychiatric diagnosis are unlike any true medical diagnosis found in the lab or with real tissue and medical evidence.…There are no biological tests, scans or lab [work] done.” Rather, psychiatric diagnoses are created by a consensus of a mental health group.[7]
• A PR Newswire about an analysis from business intelligence provider GBI Research reviewing the ADHD market in June 2015, said, “While marketed therapies treat ADHD symptoms, they are not curative; fundamental causes of the disease remain unknown.” Yet, there are 68 “therapies” currently being developed to treat ADHD.[8] Already coming off the pipeline is the chewable tablet form of extended-release methylphenidate (called QuilliChew ER), which was approved by the FDA in December 2015 for children aged 6 years and older.[9]

Mr. Luis is concerned that the more stimulants get approved by the FDA, the more the risk is of children and teenagers also abusing them. Because Adderall and other stimulants are prescription drugs, students misleadingly think they are not dangerous at all.[10] But DeAnsin Parker, a New York City clinical neuropsychologist, says that when people try to stop using ADHD drugs, they may experience extreme mood swings and behave strangely or unpredictably. The symptoms are “all the things that we see if someone were getting off a cocaine addiction,” Parker stated.[11]

This is information the Los Angeles family was never given and it took research and looking for non-harmful medical alternatives to psychiatric labels and drugs to ensure the grandchildren were never drugged. As a public information mental health rights group, CCHR provides parents with facts from which they can make informed decisions about their health care and behavioral needs.

About Citizens Commission on Human Rights: CCHR is a non-profit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR has helped to enact more than 150 laws protecting individuals from abusive or coercive mental health practices.

References:

[1] “Adderall abuse linked to heart disease, Parkinson's,” Fox 8 News, 19 Feb 2016, fox8live.com/story/31269203/adderall-abuse-linked-to-heart-disease-parkinsons.

[2] Drug Fact Sheet, Amphetamines, Drug Enforcement Agency, dea.gov/druginfo/drug_data_sheets/Amphetamines.pdf; deadiversion.usdoj.gov/schedules/; dea.gov/druginfo/ds.shtml.

[3] “Adderall abuse linked to heart disease, Parkinson's,” Fox 8 News, 19 Feb 2016, fox8live.com/story/31269203/adderall-abuse-linked-to-heart-disease-parkinsons.

[4] “Adderall misuse rising among young adults,” CBS News, 16 Feb. 2016, cbsnews.com/news/adderall-misuse-rising-among-young-adults/

[5] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Years 2008-2013, Extracted 2014, cchrint.org/psychiatric-drugs/stimulantsideeffects/adderallsideeffects/people-taking-adderall/.

[6] “What is attention-deficit hyperactivity disorder (ADHD)?” J. Child Neur. 2005 Dec;20(12):994-1002, ncbi.nlm.nih.gov/pubmed/16417850.

[7] “Subjective Diagnosis and Limitations to Psychiatric Diagnosis,” Dr. Toby Watson, drtobywatson.com/diagnosis.html.

[8] “Treatment Market Value for Attention-Deficit Hyperactivity Disorder to Exceed $13 Billion by 2020,” PR Newswire, June 12, 2015, prnewswire.com/news-releases/treatment-market-value-for-attention-deficit-hyperactivity-disorder-to-exceed-13-billion-by-2020-507101171.html.

[9] Megan Brooks, “FDA Clears Chewable Methylphenidate (QuilliChew) for ADHD,” Medscape, 7 Dec 2015, medscape.com/viewarticle/855572

[10] Arianna Yanes, “Just say yes? The rise of 'study drugs' in college,” CNN, April 18, 2014, cnn.com/2014/04/17/health/adderall-college-students/.

[11] Amanda Leigh Mascarelli, “‘Study drugs’ can be dangerous, Misusing prescription drugs to improve school performance isn’t just dangerous. It’s cheating.” Science News, Society for Science, October 25, 2013, student.societyforscience.org/article/study-drugs-can-be-dangerous.

Media Department, Citizens Commission on Human Rights, http://www.cchrint.org, +1 (323) 467-4242, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.